Astellas Logs Sales Growth in Q1, but Profits Drop Sharply on Write-Offs

Astellas Pharma saw its sales grow over 6% in the first quarter of FY2021, but its profits tumbled due to impairment losses incurred from the termination of development projects, including its peanut allergy vaccine ASP0892. In April-June, the Japanese company...read more